The anti-hepatocellular carcinoma cell activity by a novel mTOR kinase inhibitor CZ415

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Dysregulation of the mammalian target of rapamycin (mTOR) pathway is implicated in hepatocellular carcinoma (HCC) development and progression.
• Targeting mTOR offers a potential therapeutic strategy for HCC, necessitating the development of potent and selective inhibitors.

Purpose of the Study:

• To evaluate the efficacy and mechanism of action of CZ415, a novel mTOR kinase inhibitor, in hepatocellular carcinoma (HCC) models.
• To assess CZ415's effects on HCC cell survival, proliferation, and apoptosis, and its safety in normal hepatocytes.

Main Methods:

• In vitro assessment of CZ415 on HCC cell lines (HepG2, Huh-7) and primary HCC cells, measuring survival, apoptosis, and proliferation.
• Mechanistic studies in HepG2 cells to investigate CZ415's impact on mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) assembly and activation.
• In vivo efficacy studies using HepG2 xenografts in severe combined immuno-deficient (SCID) mice treated with CZ415.

Main Results:

• CZ415 demonstrated potent inhibition of HCC cell survival and induced apoptosis at nanomolar concentrations, outperforming existing mTORC1 inhibitors.
• CZ415 effectively inhibited HCC cell proliferation and was non-cytotoxic to normal human hepatocytes (L02 cells).
• Mechanistic studies revealed CZ415 disrupts both mTORC1 and mTORC2 assembly, blocking key signaling pathways (p-S6K1, p-AKT).
• In vivo, oral administration of CZ415 significantly suppressed tumor growth in a HepG2 xenograft model, with concurrent inhibition of mTORC1/2 activation in tumor tissues.

Conclusions:

• CZ415 is a potent inhibitor of both mTORC1 and mTORC2, demonstrating significant anti-cancer activity against hepatocellular carcinoma.
• CZ415 exhibits promising therapeutic potential for HCC, showing efficacy in vitro and in vivo with a favorable safety profile in normal hepatocytes.